Background: Recent studies in severely injured patients suggest an important role of von Willebrand Factor (VWF) and ADAMTS13 in the endotheliopathy of trauma (EoT). We hypothesized that the early use of cryoprecipitate would be effective as an endothelial protector by supplementing physiologic VWF and ADAMTS13 to reverse the EoT. We tested a pathogen-reduced lyophilized cryoprecipitate (LPRC) that could expedite the early administration of cryoprecipitate in the battlefield.
Methods: A mouse multiple-trauma model with uncontrolled hemorrhage (UCH) from liver injury was utilized followed by hypotensive resuscitation (mean arterial pressure, 55-60) × 3 hours with lactated Ringer's (LR), fresh frozen plasma (FFP), conventional pathogen-reduced cryoprecipitate (CC), and LPRC. Blood was collected for measurement of syndecan-1, VWF, and ADAMTS13 by ELISA. Lungs were stained for histopathologic injury and syndecan-1 and bronchial alveolar lavage (BAL) fluid harvested for protein as an indicator of permeability. Statistical analysis was by ANOVA followed by Bonferroni correction.
Results: Following multiple trauma and UCH, blood loss was similar across groups. Mean volume of resuscitation was higher in the LR group compared with the other resuscitation groups. Lung histopathologic injury, syndecan-1 immunostaining and BAL protein were higher with LR compared with resuscitation with FFP and CC, while LPRC further reduced BAL compared with FFP and CC. The ADAMTS13/VWF ratio was significantly lower in LR but improved with FFP and CC, comparable to shams while LPRC further increased this ratio.
Conclusion: The protective effects of CC and LPRC were comparable to FFP in ameliorating the EoT in our murine multiple trauma and UCH model. Lyophilized cryoprecipitate may also provide additional benefit by enhancing the ADAMTS13/VWF ratio. These data provide evidence of the safety and efficacy of LPRC and warrants further investigation for its potential application in military settings once approved for human administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389395 | PMC |
| http://dx.doi.org/10.1097/TA.0000000000004065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation of a Bleeding Management Algorithm in Liver Transplantation: A Pilot Study.
Transfus Med Hemother
February 2024
Department for Anesthesiology and Critical Care, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Objectives: The aims of the study were to compare the consumption of blood products before and after the implementation of a bleeding management algorithm in patients undergoing liver transplantation and to determine the feasibility of a multicentre, randomized study.
Background: Liver transplantation remains the only curative therapy for patients with end-stage liver disease, but it carries a high risk of surgical bleeding.
Materials And Methods: Retrospective study of patients treated before (group 1) and after (group 2) implementation of a haemostatic algorithm guided by viscoelastic testing, including use of lyophilized coagulation factor concentrates ().
Immediate use cryoprecipitate products provide lasting organ protection in a rodent model of trauma/hemorrhagic shock and prolonged hypotensive resuscitation.
J Trauma Acute Care Surg
October 2023
From the Shock Trauma Center (A.Z., F.W., S.C., R.A.K.), University of Maryland School of Medicine, Baltimore, Maryland; Cerus Corporation (L.C.), Concord; Department of Laboratory Medicine, University of California (S.P.), San Francisco, San Francisco, California.
Background: Cryoprecipitate (CP) can augment hemostasis after hemorrhagic shock (HS). Similar to fresh frozen plasma (FFP), CP may provide short-term endothelial protection. We tested a new 5-day postthaw CP (5-day pathogen-reduced cryoprecipitate [5PRC]) and lyophilized pathogen-reduced cryoprecipitate (LPRC) to overcome challenges of early administration and hypothesized that 5PRC and LPRC would provide lasting organ protection in a rodent model of HS.
View Article and Find Full Text PDFEarly lyophilized cryoprecipitate enhances the ADAMTS13/VWF ratio to reduce systemic endotheliopathy and lessen lung injury in a mouse multiple-trauma hemorrhage model.
J Trauma Acute Care Surg
August 2023
From the Shock Trauma Center and the University of Maryland School of Medicine (A.Z., F.W., R.A.K.), Baltimore, Maryland; Bloodworks Research Institute and Hematology Division, Department of Medicine (J.-F.D.), University of Washington School of Medicine, Seattle, Washington; Shock Trauma Anesthesiology Research (STAR) Center and Department of Epidemiology (R.V.), University of Maryland School of Medicine, Baltimore, Maryland; Trauma and Transfusion Medicine Research Center, Department of Surgery (M.D.N.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Cerus Corporation (L.C.), Concord, California; and Department of Laboratory Medicine (S.P.), University of California San Francisco, San Francisco, California.
Background: Recent studies in severely injured patients suggest an important role of von Willebrand Factor (VWF) and ADAMTS13 in the endotheliopathy of trauma (EoT). We hypothesized that the early use of cryoprecipitate would be effective as an endothelial protector by supplementing physiologic VWF and ADAMTS13 to reverse the EoT. We tested a pathogen-reduced lyophilized cryoprecipitate (LPRC) that could expedite the early administration of cryoprecipitate in the battlefield.
View Article and Find Full Text PDFAchieving haemostasis in thrombocytopenia in remote settings: an in vitro comparison of frozen and lyophilized products.
Blood Transfus
July 2023
ACRF Dept. Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Article Synopsis
- Platelet concentrates have a short shelf life and are often impractical for use in low-turnover areas, leading researchers to explore cryopreserved platelets and fibrinogen concentrates as alternatives for treating thrombocytopenia.
- In a study with severe thrombocytopenia patients, cryopreserved platelets were found to improve clotting times but did not enhance clot strength, while cryoprecipitate showed potential for correcting thromboelastometry parameters.
- The findings suggest that while cryopreserved platelets can initiate clotting, cryoprecipitate may be a valuable substitute when platelets are not available; however, more clinical studies are needed to validate these results.
Comprehensive care for hemophilia and other inherited bleeding disorders.
Transfus Apher Sci
October 2019
National Director of Health Policy, Canadian Hemophilia Society Montreal, Canada. Electronic address:
The World Federation of Hemophilia (WFH) states in its Guidelines for the Management of Hemophilia, Second Edition [1], that people with hemophilia are best managed in a comprehensive care setting. That team is typically comprised of a core group including a hematologist, nurse coordinator, physiotherapist, social worker, specialized lab technologist and data manager, and as needed, by other specialists. Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!